Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | APOB | P04114 | 9/20 | 0.50 |
| ▸ | MTTP | P55157 | 8/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805325 | 1.00 | KCNMA1 (0.51) | KCNMA1APOBMTTPP2RX1ALDH1A1 | |
| SCHEMBL6804166 | 0.84 | SMO (0.61) | KCNMA1APOBMTTPP2RX1ABCG2 | |
| SCHEMBL6794883 | 0.83 | P2RX1 (0.56) | KCNMA1APOBMTTPP2RX1ALDH1A1 | |
| SCHEMBL6801792 | 0.83 | TP53 (0.56) | APOBMTTPP2RX1ALDH1A1MAPT | |
| SCHEMBL6798429 | 0.83 | SMO (0.57) | KCNMA1APOBMTTPP2RX1MAPT | |
| SCHEMBL6809184 | 0.82 | SMO (0.56) | KCNMA1APOBMTTPP2RX1MAPT | |
| SCHEMBL14031525 | 0.79 | KCNMA1 (0.66) | KCNMA1APOBMTTPP2RX1ALDH1A1 | |
| SCHEMBL6794433 | 0.78 | ABCG2 (0.70) | APOBMTTPP2RX1ALDH1A1MAPT | |
| SCHEMBL7085366 | 0.78 | SMO (0.53) | KCNMA1APOBMTTPP2RX1TRPV1 | |
| SCHEMBL5113527 | 0.77 | KMT2A (0.70) | KCNMA1ALDH1A1MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | KCNMA1 1807/4885APOB 1/4885MTTP 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.